Definition of An Optimal First-line Chemotherapy in Metastatic Breast Cancer |
| |
Authors: | Volker Heinemann |
| |
Affiliation: | 1.Department of Medical Oncology, Medical Clinic III,University Hospital of Munich, Klinikum Grosshadern,Munich,Germany |
| |
Abstract: | Single-agent chemotherapy of metastatic breast cancer is the treatment of choice in patients with slow tumor progression and asymptomatic disease. In this patient group, the choice of drugs is based more on good tolerability than on efficacy. By contrast, symptomatic or rapidly progressing disease requires the use of highly active regimens where more weight is put on reliable antitumor activity. While anthraycline-based combination regimens have set the standard of effective treatment, the addition of docetaxel (and to a lesser extent paclitaxel) has improved tumor response, but failed to induce a consistent prolongation of survival. Based on retrospective analyses, it is hypothesised that the combined use of anthracyclines and taxanes in first-line therapy may be most beneficial in defined subgroups: after adjuvant chemotherapy, in patients with HER-2 gene amplification, possibly also in patients with rapidly progressing visceral disease. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|